Opis

• Tytuł:
  Thalidomide - a chance for use in modern disease treatment?
• Twórca:
  Turek, Marta;
  Szlążek, Julia;
  Zagalska, Michalina;
  Ząbek, Adam Jan;
  Kuźniar, Jakub Paweł;
  Chrzanowska, Emilia Gabriela;
  Tamborski, Tomasz;
  Grzebinoga, Adam;
  Roguska, Barbara
• Opis:
  Thalidomide, despite its controversial history associated with teratogenic effects is currently used in the treatment of various conditions including oncological, immunological and dermatological diseases. The drug exhibits anti-inflammatory, immunomodulatory and anti-angiogenic effects, making it potentially effective in the treatment of various diseases. The mechanism of action is based on modulating the CRL4CRBN E3 ubiquitin ligase complex by binding to cereblon (CRBN), which leads to a change in the substrates recognized by this complex and the degradation of specific proteins. Thalidomide is used in the treatment of multiple myeloma, especially in cases resistant to other treatment methods. In addition, it can support the treatment of glioblastoma multiforme due to its anti-angiogenic and immunomodulatory effects. It is also used in the treatment of Crohn's disease, systemic lupus erythematosus, and idiopathic pulmonary fibrosis (IPF). In Crohn's disease it works by blocking TNF-α and modulating the immune response. In cutaneous lupus erythematosus it reduces inflammation, modulates the immune response and inhibits angiogenesis. In IPF, it inhibits the production of pro-inflammatory cytokines and reduces oxidative stress. The use of thalidomide is associated with a risk of teratogenicity, which requires strict control and the use of effective methods of contraception. In addition thalidomide can cause side effects, mainly hematological and gastrointestinal disorders. Due to the side effect profile, the use of thalidomide requires caution and close monitoring of the patient by a physician.
• Dostępność obiektu:
  Dostęp otwarty
• Prawa: https://creativecommons.org/licenses/by-nc-sa/4.0 ;
  Prawa autorskie (c) 2025 Marta Turek, Julia Szlążek, Michalina Zagalska, Adam Jan Ząbek, Jakub Paweł Kuźniar, Emilia Gabriela Chrzanowska, Tomasz Tamborski, Adam Grzebinoga, Barbara Roguska
• Data:
  2025.05.07
• Typ:
  info:eu-repo/semantics/article;
  info:eu-repo/semantics/publishedVersion
• Język:
  angielski
• Źródło:
  Journal of Education, Health and Sport; Vol. 81 (2025); 59794;
  Journal of Education, Health and Sport; Tom 81 (2025); 59794;
  2391-8306
• Format:
  application/pdf
• Wydawca:
  Nicolaus Copernicus University, Toruń, Poland
• Relacja: https://apcz.umk.pl/JEHS/article/view/59794/42431
• Temat i słowa kluczowe:
  thalidomide;
  molecular mechanism;
  teratogenic effect;
  anti-inflammatory effect;
  immunomodulation;
  anti-angiogenesis;
  treatment
• Identyfikator: https://apcz.umk.pl/JEHS/article/view/59794
• Dostawca danych:
  Akademicka Platforma Czasopism
• Czy mogę z tego obiektu skorzystać?:
  poproś o pozwolenie
• Rodzaj zawartości:
  teksty